Published: 12 April 2018
Author(s): Marco Proietti, Stefania Antoniazzi, Valter Monzani, Paola Santalucia, Carlotta Franchi, SIM-AF Investigators
Issue: April 2018
Section: Letter to the Editor

Atrial fibrillation (AF) is independently associated with a higher risk of morbidity and mortality, in particular with an increased risk of thromboembolic events [1]. Use of oral anticoagulant (OAC) drugs reduces the risk of stroke and systemic embolism, as well as mortality among patients with AF [1].

Newsletters

Stay informed on our latest news!